The coronavirus pandemic has made this a challenging year for everyone. Our thoughts are with the many who have suffered, especially those with resulting life-threatening conditions, and those who have lost their jobs or their businesses. Cumberland is grateful to be part of an industry that is playing a key role in fighting back.

Through it all, our facilities have remained open and our operations continue as normal. We are proud of our team’s steadfast dedication to protecting our nation’s health during these unprecedented times.

Some recent highlights include:

- Vibativ®, a potent antibiotic designed to treat hard-to-treat infections, is being used to help COVID-19 patients with bacterial infections in their lungs. It is approved to treat hospital- and ventilator-acquired pneumonia that can result from COVID-19, the flu and other infections. We’ve heard stories from around the country of Vibativ successfully curing patients of pneumonia, which has been tremendously rewarding.

- We announced two favorable study publications for Caldolor®, our injectable ibuprofen. One study demonstrated significant reduction of opioid use in orthopedic trauma patients. The second study supported the use of Caldolor for post-operative pain, reducing the use of opioids and over-the-counter medications.

We have a lot to look forward to moving into 2021. We are getting ready to introduce our newly FDA-approved RediTrex® product line, which we plan to soft launch by the end of 2020 and launch commercially next spring. We believe it will be a valuable addition to our portfolio.

While the pandemic has impacted hospital admissions and physician office visits, which led to enrollment interruptions in our clinical studies, we are very fortunate that our business has remained steady. Our product portfolio of FDA-approved brands delivered combined revenues of $9.3 million during the third quarter. We posted both sequential and year over year revenue growth, which was no small feat in the pandemic operating environment. That speaks to the durability of our product portfolio and commitment of our commercial organization.  

We are confident that we have the key pieces in place to help us build our business and deliver our goal of improving patient care through the delivery of high-quality medicines. For more information on our products, including full prescribing information, please visit the individual product websites, links to which can be found on our corporate site.